Tags

Type your tag names separated by a space and hit enter

Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 07; 92(7):814-818.JM

Abstract

Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6), emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and IL-6 before and after TCZ therapy and clinical outcome in the 15 COVID-19 patients were retrospectively assessed. Totally 15 patients with COVID-19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL-6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL-6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL-6, the repeated dose of the TCZ is recommended.

Authors+Show Affiliations

Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32253759

Citation

Luo, Pan, et al. "Tocilizumab Treatment in COVID-19: a Single Center Experience." Journal of Medical Virology, vol. 92, no. 7, 2020, pp. 814-818.
Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-818.
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020). Tocilizumab treatment in COVID-19: A single center experience. Journal of Medical Virology, 92(7), 814-818. https://doi.org/10.1002/jmv.25801
Luo P, et al. Tocilizumab Treatment in COVID-19: a Single Center Experience. J Med Virol. 2020;92(7):814-818. PubMed PMID: 32253759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab treatment in COVID-19: A single center experience. AU - Luo,Pan, AU - Liu,Yi, AU - Qiu,Lin, AU - Liu,Xiulan, AU - Liu,Dong, AU - Li,Juan, Y1 - 2020/04/15/ PY - 2020/03/22/received PY - 2020/03/26/revised PY - 2020/03/26/accepted PY - 2020/4/8/pubmed PY - 2020/6/25/medline PY - 2020/4/8/entrez KW - COVID-19 KW - SARS-CoV-2 KW - Tocilizumab KW - cytokine storms KW - interleukin-6 SP - 814 EP - 818 JF - Journal of medical virology JO - J. Med. Virol. VL - 92 IS - 7 N2 - Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6), emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and IL-6 before and after TCZ therapy and clinical outcome in the 15 COVID-19 patients were retrospectively assessed. Totally 15 patients with COVID-19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL-6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL-6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL-6, the repeated dose of the TCZ is recommended. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/32253759/Tocilizumab_treatment_in_COVID_19:_A_single_center_experience_ L2 - https://doi.org/10.1002/jmv.25801 DB - PRIME DP - Unbound Medicine ER -